Acceleron Pharma (XLRN) Misses Q4 EPS by 14c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Barclays Starts Acceleron Pharma (XLRN) at Overweight
February 27, 2020 6:57 AM ESTBarclays analyst Carter Gould initiates coverage on Acceleron Pharma (NASDAQ: XLRN) with a Overweight rating and a price target of $107.00.
For an analyst ratings summary and ratings history on Acceleron Pharma click here. For more ratings news on Acceleron Pharma click here.
Shares of Acceleron Pharma closed at $87.36 yesterday.
... More